AnnJi Pharmaceutical Moves AJ201 into Phase 3 Trial for Kennedy’s Disease

The ROMA-KD study is a global, randomized, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of AJ201 in approximately 200 ambulatory patients. The drug works by promoting the clearance of pathogenic mutant androgen receptor proteins while activating critical stress-response pathways, including Nrf1, Nrf2, and HSF1. This mechanism positions the candidate as a potential first-in-class treatment for the rare, X-linked neuromuscular disorder.

Dr. Wendy Huang, Chairperson and CEO of AnnJi, emphasized that the trial’s progress reflects a commitment to families navigating the daily physical challenges of the disease. To further align its research with lived experience, the company established a Patient and Care Partner Advisory Council in collaboration with the Kennedy's Disease Association. This forum allows patients to contribute insights on study design and accessibility, operating independently from the clinical trial process to ensure objective, patient-centered development.